134 related articles for article (PubMed ID: 35094253)
1. An Individualized EMT-Related Gene Signature to Predict Recurrence-Free Survival in Stage II/III Colorectal Cancer Patients.
Zhang W; Zhang X; Zhao D; Hu M; Ge X; Xia L
Dig Dis Sci; 2022 Nov; 67(11):5116-5126. PubMed ID: 35094253
[TBL] [Abstract][Full Text] [Related]
2. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer.
Matsuyama T; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kawano T; Uetake H; Goel A
Mol Cancer; 2019 Feb; 18(1):19. PubMed ID: 30717807
[TBL] [Abstract][Full Text] [Related]
4. Identification of an EMT-related Gene Signature Predicting Recurrence in Stage II/III Colorectal Cancer: A Retrospective Study in 1780 Patients.
Ren H; Bösch F; Pretzsch E; Jacob S; Westphalen CB; Walter Holch J; Werner J; Angele MK
Ann Surg; 2022 Nov; 276(5):897-904. PubMed ID: 35880752
[TBL] [Abstract][Full Text] [Related]
5. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
6. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel prognostic signature correlated with epithelial-mesenchymal transition, N6-methyladenosine modification, and immune infiltration in colorectal cancer.
Qu X; Tan H; Mao J; Yang M; Xu J; Yan X; Wu W
Cancer Med; 2023 Mar; 12(5):5926-5938. PubMed ID: 36281556
[TBL] [Abstract][Full Text] [Related]
8. KRT17 as a prognostic biomarker for stage II colorectal cancer.
Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
[TBL] [Abstract][Full Text] [Related]
9. Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes.
Wang K; Song K; Ma Z; Yao Y; Liu C; Yang J; Xiao H; Zhang J; Zhang Y; Zhao W
Br J Cancer; 2020 Aug; 123(3):410-417. PubMed ID: 32435058
[TBL] [Abstract][Full Text] [Related]
10. Genomics and prognosis analysis of epithelial-mesenchymal transition in colorectal cancer patients.
Zhang Z; Zheng S; Lin Y; Sun J; Ding N; Chen J; Zhong J; Shi L; Xue M
BMC Cancer; 2020 Nov; 20(1):1135. PubMed ID: 33228590
[TBL] [Abstract][Full Text] [Related]
11. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
[TBL] [Abstract][Full Text] [Related]
12. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.
Tian X; Zhu X; Yan T; Yu C; Shen C; Hu Y; Hong J; Chen H; Fang JY
Mol Oncol; 2017 Nov; 11(11):1544-1560. PubMed ID: 28796930
[TBL] [Abstract][Full Text] [Related]
13. Integrated analysis identifies an immune-based prognostic signature for the mesenchymal identity in colorectal cancer.
Zhang B; Wang L; Liu Z; Shao B; Jiang W; Shu P
Medicine (Baltimore); 2020 Jun; 99(25):e20617. PubMed ID: 32569190
[TBL] [Abstract][Full Text] [Related]
14. A novel 9-gene signature for the prediction of postoperative recurrence in stage II/III colorectal cancer.
Xin C; Lai Y; Ji L; Wang Y; Li S; Hao L; Zhang W; Meng R; Xu J; Hong Y; Lou Z
Front Genet; 2022; 13():1097234. PubMed ID: 36704343
[No Abstract] [Full Text] [Related]
15. An
Han Y; Wong FC; Wang D; Kahlert C
Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
[TBL] [Abstract][Full Text] [Related]
17. Colorectal obstruction is a potential prognostic factor for stage II colorectal cancer.
Okuda Y; Shimura T; Yamada T; Hirata Y; Yamaguchi R; Sakamoto E; Kataoka H
Int J Clin Oncol; 2018 Dec; 23(6):1101-1111. PubMed ID: 29948240
[TBL] [Abstract][Full Text] [Related]
18. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
20. A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer.
Sho S; Court CM; Winograd P; Russell MM; Tomlinson JS
J Surg Oncol; 2017 Dec; 116(8):996-1004. PubMed ID: 28767131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
